Syros’ SY-1365 Displays Punch Against Ovarian Cancer, Studies Show

Syros’ SY-1365 Displays Punch Against Ovarian Cancer, Studies Show
Syros Pharmaceuticals’ investigational compound SY-1365 showed potent anticancer activity in cell and animal models of ovarian cancer, giving the company momentum to move toward the Phase 1 trial it plans later this year. SY-1365 was also active against breast cancer and lung cancer, Syros said at the American Association of Cancer Research (AACR) 2017 Annual Meeting in Washington. Its presentation was titled "SY-1365, a potent and selective CDK7 inhibitor, exhibits promising anti-tumor activity in multiple preclinical models of aggressive solid tumors." The treatment targets cancer by blocking a molecule known as CDK7, for cyclin-dependent kinase 7, Many cancers’ growth and survival are dependent on the activation of specific genes, and SY-1365 interferes with gene activation, which scientists call transcription. Syros is also developing drugs to target CDK12 and CDK13, which belong to the same family of proteins as CDK7. “SY-1365, our first-in-class selective CDK7 inhibitor, as well as our CDK12 and CDK13 inhibitor program, highlight the power of our gene control platform to selectively target transcription and potentially treat diseases that have been underserved by other genomic-based approaches,” Nancy Simonian, MD, chief executive officer of Syros, said in a press release. “These new data show SY-1365 reduces proliferation and induces apoptosis [programmed cell death] in cancer cells in several difficult-to-treat tumors. The re
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *